Physicians should encourage pharmaceutical companies to make socially responsible funding decisions and take an active role in setting biomedical research priorities by advocating for fair and effective allocations of public and private biomedical R & D investments.
A Canadian physician reports there is systematic bias to the outcome of published research funded by the pharmaceutical industry and believes more steps need to be taken to improve the integrity of clinical research reports in the United States and Canada.
A recent journal article calls for a public policy that would require physician-researchers to demonstrate the absence of undue influence or coercion on informed consent.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.